1 / 6

Drug-eluting stents for in-stent restenosis

ISAR-DESIRE Trial. Drug-eluting stents for in-stent restenosis. Presented at European Society of Cardiology Congress 2004 Presented by Dr. A. Kastrati. ISAR-DESIRE Trial. 300 patients with in-stent restenosis in a native vessel randomized to:. Balloon angioplasty n=100.

linus
Télécharger la présentation

Drug-eluting stents for in-stent restenosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ISAR-DESIRE Trial Drug-eluting stents for in-stent restenosis Presented at European Society of Cardiology Congress 2004 Presented by Dr. A. Kastrati

  2. ISAR-DESIRE Trial 300 patients with in-stent restenosis in a native vessel randomized to: • Balloon angioplasty • n=100 • Sirolimus-eluting stents • n=100 • Paclitaxel-eluting stents • n=100 • Primary Endpoint: • Restenosis in-segment at 6 month angiography, defined as stenosis ≥50% • Primary analysis for balloon angioplasty vs drug-eluting stent comparison • Secondary analysis for sirolimus-eluting stent vs paclitaxel-eluting comparison Presented at ESC 2004

  3. ISAR-DESIRE Trial Restenosis (in-segment) on 6 month angiography • Primary endpoint of in-segment restenosis on 6 month angiography ↓ in DES groups than balloon angioplasty group • For the analysis comparing the sirolimus vs paclitaxel DES, p=0.19 p<0.001 p=0.001 p=0.19 Presented at ESC 2004

  4. ISAR-DESIRE Trial Clinical target vessel revascularization at 9 months • Clinical target vessel revascularization at 9 months less frequent in DES groups than balloon angioplasty group • For the analysis comparing the sirolimus vs paclitaxel DES, clinical TVR ↓ in sirolimus DES group than paclitaxel DES group p<0.001 p=0.02 p=0.02 Presented at ESC 2004

  5. ISAR-DESIRE Trial MI by 6 months Using FRISC-2 definition p = 0.010 Using ICTUS definition p = 0.006 Using TACTICS-TIMI 18 definition p = 0.082 % Presented at ESC 2004

  6. ISAR-DESIRE Trial • Among patients with in-stent restenosis, treatment with a drug-eluting stent was associated with a lower rate of restenosis compared with balloon angioplasty • Additionally, use of sirolimus DES was associated with a lower TVR rate and smaller late lumen loss than use of paclitaxel DES in patients with in-stent restenosis • While findings are provocative, larger studies needed to validate results, given small sample size • Additionally, study was conducted in patients with in-stent restenosis, not de novo lesions, and extrapolation to other populations may not be valid • Upcoming, much larger REALITY trial will compare sirolimus versus paclitaxel DES in patients with de novo lesions

More Related